Herpes zoster infection after liver transplantation in patients receiving induction therapy with alemtuzumab

Clinical Transplantation

Volumn 22, Issue 4, 2008, Pages 502-507

  Alcaide, Maria L ^a   Abbo, Lilian ^a   Pano, Jose R ^a   Gaynor, Jeffrey J ^a   Tryphonopoulos, Panagiotis ^a   Weppler, Debbie ^a   Moon, Jang I ^a   Tzakis, Andreas G ^a   Morris, Michele I ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Alemtuzumab; Herpes; Liver; Transplantation; Zoster

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; FAMCICLOVIR; GANCICLOVIR; OKT 3; STEROID; TACROLIMUS; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; DRUG DOSE INCREASE; FEMALE; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; VESICULAR RASH;

2-AMINOPURINE; ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIVIRAL AGENTS; FEMALE; GANCICLOVIR; GRAFT SURVIVAL; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 48249083426     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00816.x     Document Type: Article

References (18)

1. Gnann JW, Whitley RJ. Herpes zoster. N Engl J Med 2002: 347: 340.
2. Gourishankar S, McDermid J, Jhangri S, Preiksaitis J. Herpes zoster infection following solid organ transplantation: Incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004: 4: 108.
3. Herrero I, Quiuroga J, Sangro B et al. Herpes zoster after liver transplantation: Incidence, risk factors and complications. Liver Transpl 2004: 10: 1140.
4. Levitsky J, Kalil A, Meza J, Hurst GE, Freifeld A. Herpes zoster infection after transplantation: A case-control study. Liver Transpl 2005: 11: 320.
5. Kim S, Youngwoo P, Hong H. Antibody engineering for the development of therapeutic antibodies. Mol Cell 2005: 20: 17.
6. Lundin J, Porwit-MacDonald A, Rossman ED et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004: 18: 484.
7. Selvaggi G, Weppler D, Tzakis A. Liver and gastrointestinal transplantation at the University of Miami. Clin Transplant 2003: 255.
8. Thursky K, Worth L, Seymour J, Prince H, Slavin M. Spectrum of infection, risk and recommendations for prophylaxis and screening among patient with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006: 132: 3.
9. Martin S, Marty F, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006: 43: 16.
10. Tryphonopoulos P, Madariaga JR, Kato T et al. The impact of Campath 1H induction in adult liver allotransplantation. Transplant Proc 2005: 37: 1203.
11. Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath 1H in delaying immune reconstitution. Blood 2002: 99: 4357.
12. Lamba R, Carrum G, Myers GD et al. Cytomegalovirus infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogenic stem cell transplantation with alemtuzumab. Bone Marrow Tranplant 2005: 36: 797.
13. Gaynor JJ, Feuer EJ, Tan CC et al. On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 1993: 88: 400.
14. Silveira F, Marcos A, Kwak E. Bloodstream infections in organ transplant recipients receiving alemtuzumab: No evidence of occurrence of organisms typically associated with profound T cell depletion. J Infect 2006: 53: 241.
15. + regulatory cells. J Am Soc Nephrol 2006: 17: 2844.
16. Peleg A, Husain S, Kwak EJ et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab humanized monoclonal CD-52 antibody. Clin Infect Dis 2007: 44: 204.
17. Geel A, Zuidema W, van Gelder T, van Doornum G, Weimar W. Successful vaccination against varicella zoster virus prior to kidney transplantation. Transplant Proc 2005: 37: 952.
18. Weinberg A, Horslen SP, Kaufman SS et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant 2006: 6: 565.